Two have been around in the pharmaceutical industry for a long time, and one is a relative newcomer. In considering this year’s pharma innovators to profile, the results of their accomplishments, not how long they have been around, steered the direction of this feature. Donna Murphy, global CEO of the recently formed agency network Havas Health & You; Abraham Gutman, president and CEO of AG Mednet; and C. David Nicholson, executive VP and chief R&D officer of Allergan, are being saluted for bringing new innovations to the fields of pharmaceutical advertising, clinical trial imaging and R&D, and their accomplishments are expected to echo into the future.

How we used VR and AR to create connections between physicians and patients.

Ocular Therapeutix struck a deal worth up to $315 million to develop a new formulation of Regeneron Pharmaceuticals’ approved drug Eylea.

People with very poor vision may benefit from using a device that recognizes faces, money and text, a small study suggests.

– New Step Forward in Ophthalmology with Cell Therapy Approach –   TOKYO and MASSACHUSETTS, Nov. 9, 2015 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas“) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, “Ocata“), a biotechnology company focused on the research and development of new therapies in […]

The first patient has been treated in Britain in a pioneering trial of a new treatment co-developed by Pfizer and derived from embryonic stem cells designed for patients with a condition that can cause blindness. Specialists at London’s Moorfields Eye Hospital said the operation, described as “successful”, was the first of 10 planned for participants […]